Seneca Reports Mixed Results from China Stem Cell Trial for Stroke

Seneca Biopharma, a Maryland-Suzhou company, reported mixed results from a China trial of its stem cell treatment for ischemic stroke. The Beijing study enrolled 23 patients with stable motor function deficits four months after a stroke. The subjects received an intracerebral injection of stem cells or placebo. Seneca said the active arm showed more improvement than the placebo group, though the results were not statistically significant. Seneca plans to sell rights to NSI-566 after it completes a merger with Leading BioSciences. More details.... Stock Symbol: (NSDQ: SNCA) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.